Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
74.95
-0.59 (-0.78%)
At close: May 22, 2026, 4:00 PM EDT
74.63
-0.32 (-0.43%)
After-hours: May 22, 2026, 7:53 PM EDT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $73.74M in the quarter ending March 31, 2026, a decrease of -86.41%. This brings the company's revenue in the last twelve months to $622.01M, up 14.09% year-over-year. In the fiscal year ending September 30, 2025, Arrowhead Pharmaceuticals had annual revenue of $829.45M with 23,258.15% growth.
Revenue (ttm)
$622.01M
Revenue Growth
+14.09%
P/S Ratio
16.97
Revenue / Employee
$874,837
Employees
711
Market Cap
10.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 829.45M | 825.90M | 23,258.15% |
| Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
| Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
| Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
| Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
| Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
| Sep 30, 2019 | 168.80M | 152.65M | 945.68% |
| Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
| Sep 30, 2017 | 31.41M | 31.25M | 19,736.48% |
| Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
| Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
| Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
| Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
| Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
| Sep 30, 2011 | 296.14K | - | - |
| Sep 30, 2010 | - | - | - |
| Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
| Sep 30, 2008 | 1.30M | 95.18K | 7.88% |
| Sep 30, 2007 | 1.21M | 746.74K | 161.88% |
| Sep 30, 2006 | 461.28K | -129.40K | -21.91% |
| Sep 30, 2005 | 590.68K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Axsome Therapeutics | 708.24M |
| BridgeBio Pharma | 579.96M |
| Krystal Biotech | 417.30M |
| Cytokinetics | 105.82M |
ARWR News
- 3 days ago - Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - MarketBeat
- 3 days ago - Arrowhead Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 9 days ago - Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near - MarketBeat
- 10 days ago - Arrowhead Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Arrowhead Pharmaceuticals Slides: Corporate presentation - Filings
- 10 days ago - Arrowhead price target raised to $46 from $35 at Bernstein - TheFly
- 15 days ago - Arrowhead price target raised to $90 from $80 at Chardan - TheFly
- 15 days ago - Arrowhead reports Q2 EPS (93c), consensus ($1.11) - TheFly